Patents by Inventor Lois M. Witters

Lois M. Witters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligonucleotide inhibition of epidermal growth factor receptor expression
    Patent number: 6187585
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human EGFR. The compositions comprise oligonucleotides complementary to mRNA targeted to nucleic acids encoding EGFR. Methods of using these oligonucleotides for inhibition of EGFR expression and for treatment of diseases such as cancers associated with overexpression of EGFR are provided.
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: February 13, 2001
    Assignees: Isis Pharmaceuticals, Inc., The Penn State Research Foundation
    Inventors: C. Frank Bennett, Allan Lipton, Lois M. Witters
  • Antisense oligonucleotide modulation of human HER-2 expression
    Patent number: 5968748
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human HER-2 (also known as c-neu, ErbB-2 and HER-2/neu). The compositions comprise antisense oligonucleoptides targeted to nucleic acids encoding HER-2. Methods of using these oligonucleotides for inhibition of HER-2 expression and for treatment of diseases such as cancers associated with overexpression of HER-2 are provided. Methods of inhibiting other growth factor receptors using antisense oligonucleotides targeted to nucleic acids encoding HER-2 are also provided.
    Type: Grant
    Filed: March 26, 1998
    Date of Patent: October 19, 1999
    Assignees: Isis Pharmaceuticals, Inc., The Penn State Research Foundation
    Inventors: C. Frank Bennett, Allan Lipton, Lois M. Witters
  • Oligonucleotide inhibition of epidermal growth factor receptor expression
    Patent number: 5914269
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human EGFR. The compositions comprise oligonucleotides complementary to mRNA targeted to nucleic acids encoding EGFR. Methods of using these oligonucleotides for inhibition of EGFR expression and for treatment of diseases such as cancers associated with overexpression of EGFR are provided.
    Type: Grant
    Filed: April 4, 1997
    Date of Patent: June 22, 1999
    Assignees: Isis Pharmaceuticals, Inc., The Penn State Research Foundation
    Inventors: C. Frank Bennett, Allan Lipton, Lois M. Witters